- Trials with a EudraCT protocol (124)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
124 result(s) found for: Ankylosing Spondylitis.
Displaying page 1 of 7.
EudraCT Number: 2013-005575-41 | Sponsor Protocol Number: CAIN457F2320 | Start Date*: 2015-03-31 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tole... | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) AT (Completed) NL (Completed) FI (Completed) NO (Completed) DK (Completed) GB (Completed) ES (Completed) SK (Completed) BG (Completed) PL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004532-18 | Sponsor Protocol Number: M10-239 | Start Date*: 2014-11-12 | |||||||||||
Sponsor Name:Abbott | |||||||||||||
Full Title: A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019263-11 | Sponsor Protocol Number: LTS11298 | Start Date*: 2010-07-08 | |||||||||||
Sponsor Name:sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: A multicenter uncontrolled extension study evaluating the long term safety and efficacy of SAR153191 in patients with Ankylosing Spondylitis (AS) | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) HU (Prematurely Ended) LT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016068-35 | Sponsor Protocol Number: DRI11073 | Start Date*: 2010-02-19 | |||||||||||
Sponsor Name:Sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) HU (Completed) ES (Completed) LT (Completed) AT (Completed) CZ (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017443-34 | Sponsor Protocol Number: NA22823 | Start Date*: 2010-11-01 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A Ph II/III seamless, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with tocilizumab v... | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) SK (Prematurely Ended) LT (Prematurely Ended) DE (Completed) IT (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000679-10 | Sponsor Protocol Number: CAIN457K2340 | Start Date*: 2017-11-16 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to as... | |||||||||||||
Medical condition: Ankylosing spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) FR (Completed) CZ (Completed) SK (Completed) FI (Completed) DK (Completed) NL (Completed) PT (Completed) PL (Completed) GR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011591-30 | Sponsor Protocol Number: CAIN457A2209E1 | Start Date*: 2010-09-21 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with moderate to severe ankylosing spondylitis | |||||||||||||
Medical condition: Ankylosing spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001090-24 | Sponsor Protocol Number: CAIN457F2314 | Start Date*: 2014-01-08 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase III multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long-term safety, tolerability and efficacy up to... | |||||||||||||
Medical condition: Ankylosing spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) ES (Completed) PT (Completed) GR (Completed) GB (Completed) BE (Completed) NO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001089-40 | Sponsor Protocol Number: CAIN457F2305E1 | Start Date*: 2013-08-27 | |||||||||||
Sponsor Name:Novartis Farma SpA | |||||||||||||
Full Title: An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis | |||||||||||||
Medical condition: Ankylosing spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) DE (Completed) NL (Completed) BG (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003636-21 | Sponsor Protocol Number: GLPG0634-CL-223 | Start Date*: 2017-01-26 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 12 weeks to subjects with active ankylosing spondylitis | |||||||||||||
Medical condition: ankylosing spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) CZ (Completed) ES (Completed) BG (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004108-37 | Sponsor Protocol Number: CC-99677-AS-001 | Start Date*: 2021-07-09 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Prematurely Ended) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004229-40 | Sponsor Protocol Number: 112008 | Start Date*: 2009-03-09 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Ankylosing Spondylitis (AS) | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001684-77 | Sponsor Protocol Number: 1407-0003 | Start Date*: 2020-12-07 | |||||||||||
Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | |||||||||||||
Full Title: A 12-weeks Phase II, randomized, double-blind, placebocontrolled, parallel-group, proof-of-concept trial of BI 730357 in patients with active ankylosing spondylitis | |||||||||||||
Medical condition: axial spondyloarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003932-11 | Sponsor Protocol Number: I1F-MC-RHBV | Start Date*: 2016-04-19 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients with ... | |||||||||||||
Medical condition: Radiographic Axial Spondyloarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) PL (Completed) NL (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024529-18 | Sponsor Protocol Number: CAIN457F2305 | Start Date*: 2011-08-02 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long term safety, tolerability and efficacy up to 2 years ... | |||||||||||||
Medical condition: Ankylosing spondylitis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000087-25 | Sponsor Protocol Number: A090913 | Start Date*: 2007-10-22 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: An open label pilot study of Zoledronate (Aclasta 5mg iv) in the treatment of Ankylosing Spondylitis | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002325-22 | Sponsor Protocol Number: I1F-MC-RHAO | Start Date*: 2013-09-26 | |||||||||||
Sponsor Name:Eli Lilly & Company | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients with Active Ankylo... | |||||||||||||
Medical condition: Spondylitis, Ankylosing | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003358-27 | Sponsor Protocol Number: HUM06-037 | Start Date*: 2008-05-02 | |||||||||||
Sponsor Name:Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin | |||||||||||||
Full Title: Phase III, multi-center, randomized, double blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with Adalimumab | |||||||||||||
Medical condition: Juvenile ankylosing spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003096-39 | Sponsor Protocol Number: 0881A3-4458-EU | Start Date*: 2009-07-29 | |||||||||||
Sponsor Name:WYETH LEDERLE | |||||||||||||
Full Title: Effects of Etanercept on Endothelial Function and Carotid Intima-Media Thickness In Patients With Active Ankylosing Spondylitis: a 52-Weeks, Randomized, Double Blind, Placebo-Controlled Study | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017488-40 | Sponsor Protocol Number: WA22908 | Start Date*: 2010-11-01 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomized, double-blind, parallel-group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) versus placebo in patients with ankylos... | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) SK (Prematurely Ended) LT (Prematurely Ended) BE (Prematurely Ended) DE (Completed) DK (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) ES (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
